Loading organizations...
§ Private Profile · Yoqne`am `illit, HaZafon, Israel
Develops the ORYOM Platform, an AI-powered intraocular robotic system for precise ophthalmic surgeries like cataract operations.
ForSight Robotics is a Yokneam Illit, Israel-based medical device company developing an artificial intelligence-powered intraocular robotic system designed for complex ophthalmic surgeries. The organization's proprietary ORYOM hardware platform assists medical professionals in performing highly precise surgical procedures for conditions such as cataracts, glaucoma, and retinal diseases to address global specialist shortages. Operating with a workforce of over 110 employees, the enterprise has secured $195 million in total venture funding, which includes a recent $125 million Series B financing round to advance its upcoming human clinical studies. Financial backing and strategic guidance for the technology's commercialization come from prominent investors like Eclipse Ventures, Mithril Capital, and The Adani Group, alongside industry advisors Fred Moll and Rony Abovitz. ForSight Robotics was officially established in the year 2020 by co-founders Moshe Shoham, Daniel Glozman, and Joseph Nathan.
ForSight Robotics has raised $195.0M across 3 funding rounds.
ForSight Robotics has raised $195.0M in total across 3 funding rounds.
ForSight Robotics has raised $195.0M across 3 funding rounds. Most recently, it raised $130.0M Series B in June 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2025 | $130M Series B | Seth Winterroth | Accel, Eclipse Ventures, Sonder Capital, Jeff Crusey, Fred Moll, M.D, Adani Group, Reiya Ventures | Announced |
| Jul 1, 2022 | $55M Series A | Jeet Adani | Accel, Borealis Ventures, Eclipse Ventures, Mithril Capital Management, Polaris Partners, Jeff Crusey, Seth Winterroth | Announced |
| Mar 1, 2021 | $10M Seed | Eclipse Ventures, Mithril Capital Management | Accel, Borealis Ventures, Polaris Partners, Jeff Crusey | Announced |
ForSight Robotics has raised $195.0M in total across 3 funding rounds.
ForSight Robotics's investors include Seth Winterroth, Accel, Eclipse Ventures, Sonder Capital, Jeff Crusey, Fred Moll, M.D, Adani Group, Reiya Ventures, Jeet Adani, Borealis Ventures, Mithril Capital Management, Polaris Partners.
ForSight Robotics is a medtech startup developing ORYOM, the first hybrid intraocular robotic ophthalmic platform for automating delicate eye surgeries like cataracts.[1][2][4] It serves eye surgeons and patients worldwide by addressing surgeon fatigue, precision challenges in microsurgery, and access barriers in underserved areas, delivering high-precision, cost-effective procedures that restore vision and improve outcomes.[1][2][4] The company has gained momentum through pre-IPO investor interest and leadership in the growing robotic-assisted eye surgery market, with recent funding trends in robotics startups signaling strong growth potential.[3]
Founded in 2020, ForSight combines expertise from top eye surgeons and robotics pioneers to balance human skill with automation, targeting millions affected by vision loss.[3][4]
ForSight Robotics was founded in 2020 by Daniel Glozman (CEO) and Moshe Shoham (Co-Founder and Chief Scientist), with Dr. Joseph Nathan as Co-Founder, President, and Chief Medical Officer.[3] Moshe Shoham brings prolific experience in medical robotics, while Dr. Nathan's ophthalmology expertise and Glozman's entrepreneurial drive sparked the venture.[3] The idea emerged from the need to automate intricate eye procedures—cataracts affect millions globally—where manual surgery demands extreme precision amid surgeon strain and limited access in remote areas.[2][4] Early traction built on assembling "the world's leading eye surgeons, robotics experts, engineers, and entrepreneurs," culminating in ORYOM's introduction as a brain-powered, heart-driven platform.[1][4]
ForSight rides the surgical robotics wave in ophthalmology, where aging populations drive cataract demand (over 28 million U.S. cases yearly) and robotics address surgeon shortages amid rising procedure volumes.[2] Timing aligns with exploding robotics funding—up in 2025—and market analyses projecting rapid growth in robotic-assisted eye surgery through AI-enhanced precision.[3] Favorable forces include global vision loss epidemics and medtech shifts toward automation, positioning ForSight to democratize elite care and influence standards like hybrid human-robot systems.[1][4] It shapes the ecosystem by pioneering intraocular robotics, potentially accelerating adoption in high-volume, error-prone eye procedures.
ForSight is primed for regulatory milestones, clinical trials, and commercial launches of ORYOM, targeting FDA clearance and global expansion amid 2025-2026 robotics hype.[3] Trends like AI integration and telemedicine will amplify its reach, evolving it from niche innovator to ecosystem leader in accessible eye care. As pre-IPO buzz builds, expect partnerships with hospitals and Big Medtech, restoring not just sight but surgical scalability worldwide—fulfilling its vision of high-precision surgery for all.[1][4]